The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The post-ER mechanism of PCSK9-mediated LDLr disposal requires the proteolytic activity of PCSK9.
“The post-ER mechanism requires the proteolytic activity of PCSK9, whereas the endosomallysosomal mechanism does not (Park et al, 2004;McNutt et al, 2007).”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as McNutt et al, 2007
The Discussion (page not provided) describes intracellular LDLR degradation in a post-ER compartment, but says only that the study does not preclude the possibility that this pathway requires PCSK9 catalytic activity. It does not establish that proteolytic activity is required for the post-ER mechanism. (LLM, conf=0.86)
Experimental — accuracy not yet measuredMutation of one residue of the PCSK9 catalytic triad abolishes its proteolytic activity and its ability to undergo processing to the C-form.
“Mutation of one of these residues abolishes the proteolytic activity of PCSK9 and its ability to undergo processing to the C-form (Benjannet et al, 2004(Benjannet et al, , 2006;;McNutt et al, 2007).”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as McNutt et al, 2007
The proteolytic activity of PCSK9 requires a catalytic triad of Asp186, His226, and Ser386.
“The proteolytic activity of PCSK9 requires a triad of residues (Asp 186, His 226 and Ser 386), which constitute the 'catalytic triad' of the protease.”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as McNutt et al, 2007
The endosomal-lysosomal mechanism of PCSK9-mediated LDLr disposal does not require the proteolytic activity of PCSK9.
“The post-ER mechanism requires the proteolytic activity of PCSK9, whereas the endosomallysosomal mechanism does not (Park et al, 2004;McNutt et al, 2007).”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as McNutt et al, 2007
PCSK9 is highly expressed in the liver and, upon secretion into plasma, binds to and enhances the degradation of LDLR in a nonenzymatic fashion, thereby increasing circulating LDL cholesterol.
“The proprotein convertase subtilisin/kexin type 9 (PCSK9) is highly expressed in the liver (2) and, upon its secretion into plasma, binds to and enhances the degradation of the LDLR in a nonenzymatic fashion (3, 4, 5, 6), thereby increasing circulating LDLc.”
From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
Flagged first, then by citations
Research works printed but not linked: 24
- Seidah, 2007, J. Mol. Med.
- Seidah, 1997, Curr. Opin. Biotechnol., 8, 602, 10.1016/S0958-1669(97)80036-5 · DOI
- Seidah, 2003, Proc. Natl. Acad. Sci. U. S. A., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
- Benjannet, 1993, Biochem. J., 294, 735, 10.1042/bj2940735 · DOI
- Molloy, 1994, EMBO J., 13, 18, 10.1002/j.1460-2075.1994.tb06231.x · DOI
- Nakayama, 1997, Biochem. J., 327, 625, 10.1042/bj3270625 · DOI
- Cheng, 1999, J. Biol. Chem., 274, 22805, 10.1074/jbc.274.32.22805 · DOI
- Naureckiene, 2003, Arch. Biochem. Biophys., 420, 55, 10.1016/j.abb.2003.09.011 · DOI
- Benjannet, 2004, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
- Baker, 1993, Curr. Opin. Cell Biol., 5, 966, 10.1016/0955-0674(93)90078-5 · DOI
- Anderson, 2002, J. Biol. Chem., 277, 12879, 10.1074/jbc.M108740200 · DOI
- Seidah, 2006, Biol. Chem., 387, 871, 10.1515/BC.2006.110 · DOI
- Lagace, 2006, J. Clin. Investig., 116, 2995, 10.1172/JCI29383 · DOI · Paper page
- Cunningham, 2007, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 · DOI · Paper page
- Abifadel, 2003, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
- Maxwell, 2004, Proc. Natl. Acad. Sci. U. S. A., 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
- Park, 2004, J. Biol. Chem., 279, 50630, 10.1074/jbc.M410077200 · DOI · Paper page
- Rashid, 2005, Proc. Natl. Acad. Sci. U. S. A., 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
- Cameron, 2006, Hum. Mol. Genet., 15, 1551, 10.1093/hmg/ddl077 · DOI · Paper page
- Zhang, 2007, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
- Reeves, 1996, Proc. Natl. Acad. Sci. U. S. A., 93, 11487, 10.1073/pnas.93.21.11487 · DOI
- Zhao, 2006, Am. J. Hum. Genet., 79, 514, 10.1086/507488 · DOI
- Maxwell, 2005, Proc. Natl. Acad. Sci. U. S. A., 102, 2069, 10.1073/pnas.0409736102 · DOI · Paper page
- Nassoury, 2007, Traffic, 8, 718, 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
Cited by
Sorted by citations
Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Self-citationThe hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion
Gustafsen, C., Kjolby, M., Nyegaard, M., Mattheisen, M., Lundhede, J., Buttenschøn, H., Mors, O., Bentzon, J. F., Madsen, P., Nykjaer, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.006 · Cited by 170
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Jonas, M. C., Costantini, C., & Puglielli, L. (2008) · The EMBO Reports · doi:10.1038/embor.2008.132 · Cited by 119
Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
Poirier, S., Mamarbachi, M., Chen, W.-T., Lee, A. S., & Mayer, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.006 · Cited by 86
Expanding biology of PCSK9: roles in atherosclerosis and beyond
Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76
Butkinaree, C., Canuel, M., Essalmani, R., Poirier, S., Benjannet, S., Asselin, M.-C., Roubtsova, A., Hamelin, J., Marcinkiewicz, J., Chamberland, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.647180 · Cited by 53
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
Susan-Resiga, D., Girard, E., Essalmani, R., Roubtsova, A., Marcinkiewicz, J., Derbali, R. M., Evagelidis, A., Byun, J. H., Lebeau, P. F., Austin, R. C., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101177 · Cited by 34
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
Roubtsova, A., Garçon, D., Lacoste, S., Chamberland, A., Marcinkiewicz, J., Métivier, R., Sotin, T., Paquette, M., Bernard, S., Cariou, B., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159217 · Cited by 22
Metadata
- Authors
- McNutt, M. C., Lagace, T. A., & Horton, J. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 282
- Issue
- 29
- Pages
- 20799-20803
- ISSN
- 0021-9258
- PMC
- PMC13276728
- Cited by
- 251
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review